Abstract
Global health and development communities lack sustainable, cost-effective, mutually beneficial solutions for infectious disease, food, water, and poverty challenges despite their regular interdependence worldwide1–7. Here, we show that agricultural development and fertilizer use in west Africa increase the devastating tropical disease schistosomiasis by fueling the growth of submerged aquatic vegetation that chokes out water access points and serves as habitat for snails that transmit Schistosoma parasites to >200 million people globally8–10. In a randomized control trial where we removed invasive submerged vegetation from water points, control sites had 124% higher fecal Schistosoma reinfection rates in schoolchildren and lower open water access than removal sites without any detectable long-term adverse effects of the removal on local water quality or freshwater biodiversity. The removed vegetation was as effective as traditional livestock feed but 41-179 times cheaper and converting the vegetation to compost yielded private crop production and total (public health plus private benefits) benefit-to-cost ratios as high as 4.0 and 8.8, respectively. Thus, we provide an economic incentive – with important public health co-benefits – to maintain cleared waterways and return nutrients captured in aquatic plants back to agriculture with great promise of breaking poverty-disease traps. To facilitate targeting and scaling of this intervention, we lay the foundation for using remote sensing technology to detect snail habitat. By offering a rare, profitable, win-win innovation for food and water access, poverty, infectious disease emergence, and environmental sustainability, we hope to inspire the interdisciplinary search for other planetary health solutions11 to the numerous and formidable, co-dependent global grand challenges of the 21st century.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
R01 TW010286
Funding Statement
This research was supported by a National Institutes of Health grant (R01GM109499) to JRR, JVR, SHS, GAD, NJ, and GR. Additionally, this research was supported by grants from the National Science Foundation (EF-1241889, DEB- 2109293, DEB-2017785), National Institutes of Health (R01TW010286), and the Indiana Clinical and Translational Sciences Institute to JRR; the National Institutes of Health (K01AI091864) and the National Science Foundation (EAR-1646708, EAR-1360330) to JVR, and the National Science Foundation (CNH grant # 1414102), Bill and Melinda Gates Foundation, National Institutes of Health (R01TW010286-01), Stanford GDP SEED (grant # 1183573-100-GDPAO), and SNAP-NCEAS (working group "Ecological levers for health: Advancing a priority agenda for Disease Ecology and Planetary Health in the 21st century") to SHS and GAD.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human sampling, drug administration, and informed consent from the parents or guardians of child participants were all overseen by the Biomedical Research Center EPLS (Espoir Pour La Sante), approved by the National Committee of Ethics for Health Research from the Republic of Senegal (Comite National d'Ethique de la Recherche en Sante; CNERS, Dakar, Senegal; Protocol #SEN14/33), and conducted in accordance with the Declaration of Helsinki III and with the International Ethical Guidelines for Biomedical Research Involving Human Subjects as set forth by the World Health Organization guidelines for good clinical practice 35. Additionally, this study was also approved by the University of South Florida Internal Review Board (Protocol #MS7_Pro00017473) and the University of Notre Dame (18-10-4951), and is registered on ClinicalTrials.gov (Record R01 TW010286). Any infected children found during data collection were offered the anti-schistosome drug praziquantel (40 mg/kg) and all human data were anonymized prior to analysis to protect the identity of participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
